Can anyone tell me how in the world BPAX will be able to file Libigel NDA application without meeting primary or secondary efficacy end points? Safety is importtant but without efficacy I am not sure. I am not a basher but I havn't heard product approved just based on safety without efficacy.
News 
Market Data 
Discover 
